Polyphor Pulled Out Of The Mire With EnBiotix Merger
Banks $10m For Inhaled Murepavadin
Just over three years, Polyphor's initial public offering in Switzerland raised CHF165m. Now, with just enough cash to get through the third quarter, it has been saved by a deal with US biotech EnBiotix.
You may also be interested in...
Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.
The Swiss firm is still examining options for the iv formulation of its novel antibiotic murepavadin even after it closed its two Phase III studies on safety concerns.
The arrival on the US eczema market of a couple of oral JAK inhibitors with stellar data on itching could provide a challenge to Sanofi and Regeneron's blockbuster Dupixent. However, Pfizer and AbbVie will have to overcome dermatologists' fears about the class-effect safety warnings their drugs come with.